Peptide Receptor Desensitization and Cycling
When a growth hormone peptide stops feeling like it used to, the problem is often at the receptor, not the vial. A physician-reviewed look at downregulation, tachyphylaxis, and why scheduled breaks restore sensitivity for some peptide classes but not others.

In this article
Key Takeaways
- Receptor desensitization means the cell hears the signal less clearly even when the dose stays the same. Chronic stimulation of GHRH and ghrelin receptors is the main reason growth hormone secretagogues are cycled.
- Downregulation (fewer receptors on the cell surface) and tachyphylaxis (faster receptor shutdown after each hit) are different mechanisms. Both reduce the pituitary response to CJC-1295, Ipamorelin, and related peptides.
- Physiologic GH release is pulsatile. Flat, continuous receptor stimulation fights the biology the peptides are trying to restore, which is why weekend-off patterns and month-long breaks exist.
- Repair peptides like BPC-157 are usually cycled for goal-based reasons (the injury healed), not because the receptor stops responding. NAD+, MOTS-c, GHK-Cu, and Thymosin Alpha-1 do not show the same chronic-stimulation pattern.
- If month four feels flat on a GH peptide, raising the dose often makes desensitization worse. A planned break, or switching to a non-cycling peptide during the pause, is the physiologic fix.
Receptor desensitization at a glance
Main affected class
Growth hormone secretagogues (CJC-1295, Ipamorelin, Sermorelin, Tesamorelin)
Core mechanism
Fewer receptors and/or faster receptor shutdown with chronic stimulation
Typical fix
3 to 4 week break, or 5-on/2-off weekly pattern
Usually not receptor-driven
BPC-157, NAD+, MOTS-c, GHK-Cu, Thymosin Alpha-1
Wrong move
Chasing fading effect by doubling the dose
Deeper guide
See the [peptide cycling chart](/blog/peptide-cycling-guide) for schedules by peptide
The Signal vs. the Receiver
Peptides are messages. Receptors are the ears that hear them. Desensitization is what happens when the message stays loud but the ears stop listening as well.
Patients on CJC-1295/Ipamorelin sometimes report that weeks one through eight feel strong, then month four feels like nothing changed. The vial is the same. The dose is the same. What changed is often receptor sensitivity at the pituitary, not peptide quality. Peptide quality is one thing PeRx controls tightly: every vial is compounded in a US-based, FDA-regulated 503A pharmacy, third-party batch-tested, and shipped fully reconstituted.
The peptide cycling chart tells you when to pause each class. This guide explains why at the receptor level, so the schedules make sense instead of feeling like arbitrary rules.
Downregulation vs. Tachyphylaxis
Downregulation means the cell pulls receptors off the surface. Fewer GHRH or ghrelin receptors sit on the pituitary cell membrane, so the same peptide dose produces a smaller growth hormone pulse.
Tachyphylaxis is a faster shutdown after each stimulation. The receptor is still there, but signaling blunts within minutes to hours of repeated hits. β-arrestin proteins are part of this braking system in G protein-coupled receptors, the family that includes GHRH and ghrelin receptors.
Camiña JP et al., "Desensitization and endocytosis mechanisms of ghrelin-activated growth hormone secretagogue receptor 1a," Endocrinology, 2004. View study
In practice both processes overlap. Chronic daily GH secretagogue use tends to produce gradual loss of effect that looks like tolerance. That is different from needing more caffeine because of habituation; here the cell biology literally reduces how much hormone gets released per signal.
| Term | What changes | What the patient feels |
|---|---|---|
| Downregulation | Fewer receptors on the cell surface | Same injection, smaller GH pulse over weeks |
| Tachyphylaxis | Receptor signal shuts down faster after each hit | Strong first weeks, rapid fade on continuous use |
| Goal-based cycling (BPC-157) | Receptors not the limiting factor | Peptide stopped when injury heals, not because it quit working |
Downregulation
- What changes
- Fewer receptors on the cell surface
- What the patient feels
- Same injection, smaller GH pulse over weeks
Tachyphylaxis
- What changes
- Receptor signal shuts down faster after each hit
- What the patient feels
- Strong first weeks, rapid fade on continuous use
Goal-based cycling (BPC-157)
- What changes
- Receptors not the limiting factor
- What the patient feels
- Peptide stopped when injury heals, not because it quit working
GHRH and Ghrelin Receptors: Where GH Peptides Hit
CJC-1295 and Sermorelin mimic growth hormone-releasing hormone (GHRH). They bind the GHRH receptor on pituitary somatotrophs and prime the cell to release growth hormone.
Ipamorelin targets the ghrelin receptor (GHS-R1a) on the same cells. It fires the release. The dual-receptor stack works because one peptide sets the stage and the other pulls the trigger.
Delhanty PJ et al., "Unsaturated fatty acids prevent desensitization of the human growth hormone secretagogue receptor," American Journal of Physiology - Endocrinology and Metabolism, 2010. View study
When either receptor is stimulated continuously without rest, the pituitary adapts. That adaptation is the biological reason behind "3 months on, 1 month off" and "5 days on, 2 days off" schedules in the cycling guide. The break gives receptors time to return toward baseline density and responsiveness.
Sermorelin is slightly different
Sermorelin has a shorter half-life than CJC-1295, so stimulation is naturally more pulsatile. Some providers run longer Sermorelin courses with only a 4-week pause every 6 to 12 months. The receptor risk is lower but not zero with daily use.
Why Pulsatile GH Release Matters
Your body does not release growth hormone as a flat line. It releases pulses, mostly during deep sleep. Flat receptor stimulation from daily injections without breaks pushes against that rhythm.
Giustina A, Veldhuis JD, "Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human," Endocrine Reviews, 1998. View study
Weekend-off patterns mimic the physiologic pause. Month-long breaks mimic the seasonal variation in receptor sensitivity seen in endocrine research. Both are attempts to keep the pharmacology aligned with how the pituitary is built to work.
This is also why the no-DAC form of CJC-1295 is preferred in many protocols: a shorter acting GHRH analog produces a pulse, not a plateau. See why we pair CJC-1295 with Ipamorelin for the pulsatile design rationale.
Which Peptides Actually Desensitize
High desensitization risk (cycle for receptor reasons): CJC-1295/Ipamorelin, Sermorelin, Tesamorelin, and other GH secretagogues.
Low desensitization risk (continuous use is common): NAD+, MOTS-c, GHK-Cu, Glutathione, and Thymosin Alpha-1. These work through cofactor replenishment, metabolic signaling, or immune modulation rather than chronic GPCR hammering.
Goal-based cycling (not receptor-driven): BPC-157 and BPC/TB-500 run for a healing window, then stop. Epitalon uses intermittent 10-day pulses by design. PT-141 is on-demand, not daily.
GH Secretagogues Peptide by Peptide
CJC-1295/Ipamorelin. The combination most associated with receptor-driven cycling. CJC-1295 (no-DAC) hits GHRH receptors; Ipamorelin hits ghrelin receptors. Both can downregulate with daily use. The standard patterns from the cycling chart: 3 months on / 1 month off, or 5 days on / 2 days off within each week.
Sermorelin. Shorter half-life (~10 minutes) means each injection is a brief pulse rather than a sustained plateau. Receptor risk is lower than CJC-1295, which is why some patients run Sermorelin for 6 to 12 months before a 4-week pause. Daily use still stimulates the same pituitary receptors; it is not immune to desensitization, just slower to accumulate.
Tesamorelin. FDA-approved GHRH analog with a distinct pharmacokinetic profile. Continuous daily use was the approved HIV lipodystrophy protocol. Off-label body-composition use often adds a 4-week break every 6 months because receptor adaptation still occurs, even with a pharmaceutical-grade molecule.
Ipamorelin alone. More selective than older GHRPs (GHRP-2, GHRP-6) because it does not spike cortisol or prolactin. Selectivity does not eliminate desensitization. Chronic ghrelin-receptor stimulation still blunts response over months if there is no rest period.
Practical default
If your provider has not specified a cycling schedule for CJC-1295/Ipamorelin, 3 months on and 1 month off is the conservative default. Track sleep quality and recovery across two full cycles before deciding the peptide "does not work for you."
IGF-1, Somatostatin, and Feedback Loops
Growth hormone secretagogues do not act in a vacuum. GH release triggers IGF-1 production in the liver. Rising IGF-1 feeds back to the hypothalamus and increases somatostatin, the hormone that brakes GH output. That negative feedback loop is part of why GH peptides can feel strong early and flat later, even before classic receptor downregulation is the whole story.
Junnila RK et al., "The GH/IGF-1 axis in ageing and longevity," Nature Reviews Endocrinology, 2013. View study
IGF-1 labs are the practical window into whether your pituitary is still responding. If IGF-1 was rising weeks 1 to 6 and plateaus weeks 10 to 12 at the same dose, desensitization or feedback saturation is likely. If IGF-1 never moved, the issue may be timing (injections not at bedtime), sleep quality, or under-eating, not receptors alone.
The goal on GH secretagogues is physiologic IGF-1 support, not chasing the top of the reference range. Supraphysiologic IGF-1 increases the feedback pressure that makes the peptide feel like it stopped working and raises monitoring concerns your provider will screen for.
When It Is Not Desensitization
Before assuming receptors are burned out, rule out the boring explanations. They are more common than patients expect.
| What changed | Why GH peptides feel flat | What to check |
|---|---|---|
| Fragmented deep sleep | Most GH pulses happen in slow-wave sleep | Sleep hygiene, DSIP, timing of injection before bed |
| Elevated cortisol blunts GH release | Cortisol and GH are antagonistic | Life load, HPA axis, Selank if prescribed |
| Chronic undereating or low protein | GH axis needs adequate substrate | Calorie and protein intake |
| Acute infection redirects resources | Temporary GH suppression is normal | Pause and resume when recovered |
| Morning injections vs bedtime | Misaligned with nocturnal GH physiology | Move to 30 to 60 minutes before sleep |
| Receptors downregulated after months of daily use | Classic tachyphylaxis pattern | Planned 3 to 4 week break |
Fragmented deep sleep
- Why GH peptides feel flat
- Most GH pulses happen in slow-wave sleep
- What to check
- Sleep hygiene, DSIP, timing of injection before bed
Elevated cortisol blunts GH release
- Why GH peptides feel flat
- Cortisol and GH are antagonistic
- What to check
- Life load, HPA axis, Selank if prescribed
Chronic undereating or low protein
- Why GH peptides feel flat
- GH axis needs adequate substrate
- What to check
- Calorie and protein intake
Acute infection redirects resources
- Why GH peptides feel flat
- Temporary GH suppression is normal
- What to check
- Pause and resume when recovered
Morning injections vs bedtime
- Why GH peptides feel flat
- Misaligned with nocturnal GH physiology
- What to check
- Move to 30 to 60 minutes before sleep
Receptors downregulated after months of daily use
- Why GH peptides feel flat
- Classic tachyphylaxis pattern
- What to check
- Planned 3 to 4 week break
See what happens if a peptide does not work for the full troubleshooting framework. Desensitization is one item on the list, not the default diagnosis. Because a PeRx provider sets your cycle and can review IGF-1 across it, the fix for a genuine plateau is a planned break, not a bigger dose.
Cycling Stacks and Combinations
Stacks complicate cycling because each peptide has its own receptor logic. A common mistake: cycling the GH peptide but running MOTS-c and NAD+ continuously and assuming the whole stack failed when only the GH leg desensitized.
GH + BPC-157. Cycle the GH secretagogue on schedule. Run BPC-157 for the injury course (4 to 8 weeks) independent of the GH break. When you pause CJC-1295/Ipamorelin, BPC may still be appropriate if the tendon or gut issue is active.
GH + Epitalon. Epitalon uses its own 10-day pulse / 3 to 6 month gap rhythm. Do not conflate Epitalon intermittent dosing with GH receptor recovery; they are separate clocks.
During a GH break. NAD+, GHK-Cu, and Thymosin Alpha-1 are common bridge peptides because they do not hammer the same pituitary receptors. They keep momentum on energy, tissue, or immune goals while GHRH and ghrelin receptors reset.
What to Do When the Effect Fades
Step one: confirm it is desensitization and not something else. Poor sleep, high stress, under-eating, or illness blunt GH output independent of receptors. Labs (IGF-1 trend) and timing of injections matter.
Step two: do not reflexively double the dose. If receptors are downregulated, more peptide often deepens the problem.
Step three: take the planned break, or switch to a non-cycling peptide during the pause. NAD+ or BPC-157 for a specific injury are common bridge options. Your provider sets the schedule.
Weeks 1–8
Strong response
Receptors are fresh. GH pulses are robust. Most patients notice sleep, recovery, or body-comp changes in this window.
Weeks 9–12
Plateau risk
Without a break or weekend-off pattern, receptor downregulation can flatten the response. This is when "it stopped working" complaints appear.
3–4 week pause
Receptor recovery
Time off allows GHRH and ghrelin receptor sensitivity to reset. The next cycle often feels like month one again at the same dose.
How PeRx Protocols Handle This
PeRx providers prescribe peptide therapy; they do not sell open-ended stacks without a plan. GH secretagogue prescriptions typically include a cycling structure from the start, not as an afterthought when effect fades.
If you are comparing a research-vendor "run it forever" protocol with a physician-led one, the cycling requirement is a feature. It matches pituitary biology and keeps the peptide effective across repeat courses.
Peptide Receptor Desensitization and Cycling: Common Questions
Related Guides
Continue reading about peptides and protocols that pair well with this guide.
Where to Get Peptides in San Diego (2026 Guide)
A plain guide to peptide therapy in San Diego: what it costs across coastal clinics, med spas, and telehealth, and who tends to use it here. Plus how pharmaceutical-grade peptides reach any San Diego County address without a clinic visit.
Best Peptides for Men Over 40: What Actually Works
After 40, men face declining growth hormone (about 14% per decade), slower recovery, stubborn belly fat, lighter sleep, and injuries that linger. Peptide therapy targets these specific changes. This guide ranks the most relevant peptides and explains what realistic results look like.
Phoenix Peptide Therapy: 2026 Valley of the Sun Guide
A plain guide to peptide therapy across metro Phoenix: what it costs at Valley clinics, med spas, and telehealth, who tends to use it here, and how pharmaceutical-grade peptides reach any Phoenix-area address without a drive across town.
Ready to get started?
PeRx connects you with licensed providers who prescribe peptide therapy with cycling structures matched to how each peptide class works. Vials ship ready to use from licensed 503A pharmacies.
Medical Disclaimer
The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.
The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.
The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.
Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.
Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.